Schizophrenia and diabetes: epidemiological data (Q31031816)

28 June 2017

1 reference

title

Schizophrenia and diabetes: epidemiological data (English)

1 reference

28 June 2017

0 references

Rouillon F

1

1 reference

PubMed ID

16459249

28 June 2017

Sorbara F

series ordinal

2

1 reference

PubMed ID

16459249

28 June 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

28 June 2017

1 reference

28 June 2017

20 Suppl 4

1 reference

28 June 2017

S345-8

1 reference

Phenothiazines and Diabetes in Hospitalized Women

28 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Physical consequences of schizophrenia and its treatment: the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Family history of type 2 diabetes in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Prevalence and correlates of diabetes in national schizophrenia samples.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Diabetes mellitus in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

The clinical implications of impaired glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Serum leptin levels increase rapidly after initiation of clozapine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Schizophrenic patients: physical health and access to somatic care.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Juvenile onset diabetes and schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-9338%2805%2980189-0

7 January 2021

10.1016/S0924-9338(05)80189-0

Identifiers

DOI

1 reference

28 June 2017

1 reference

PubMed ID

16459249